Today: 9 April 2026
Subscribe
Browse Category

Pharmaceutical News 13 August 2025 - 3 December 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb shares jumped over 6% to $51.32 intraday on December 3, 2025, after the company announced a data review and patient re-enrollment for its ADEPT-2 Alzheimer’s psychosis trial. The stock rally follows strong Q3 results and analyst upgrades, despite ongoing legal risks and looming patent expiries.
3 December 2025
····
CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health Stock on December 2, 2025: Insulin Settlement, Analyst Targets and What’s Next for NYSE: CVS

CVS Health shares fell 1.9% to $77.62 on December 2, 2025, underperforming the S&P 500 and healthcare peers after news of a $37.76 million federal settlement over insulin-pen billing. Trading volume topped 7.7 million shares, above average. The stock remains up about 75–80% for the year but sits roughly 8–9% below its late October high. CVS did not admit liability in the settlement.
3 December 2025
···
InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals (INM) Soars on Alzheimer’s Breakthrough: INM‑901 Study Sparks 20%+ Stock Rally on November 20, 2025

InMed Pharmaceuticals shares surged over 20% in after-hours and pre-market trading following new preclinical data for its Alzheimer’s candidate INM-901. The company reported successful large-animal studies showing robust bioavailability and no adverse neurological effects. INM traded in the $1.49–$1.55 range Thursday morning on heavy volume, with market cap estimates between $3–5 million.
20 November 2025
···
Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine (CMND) Delivers Positive AUD Trial Data Amid New Depression Patent – Nov. 18, 2025

Clearmind Medicine reported positive safety results from the first cohort of its FDA-approved Phase I/IIa trial of CMND-100 for alcohol use disorder. No serious adverse events were observed among six participants treated at Johns Hopkins and Yale. CMND shares surged to $0.39 intraday on heavy volume before settling near $0.27 by mid-afternoon November 18. The company also announced a new Israeli patent filing and an expected equity offering.
18 November 2025
··
Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma (CANF) Soars on 9-Year Liver Cancer Survival Breakthrough with Namodenoson – November 18, 2025

Can-Fite BioPharma shares surged over 30% Tuesday after reporting a patient with advanced hepatocellular carcinoma remained cancer-free for nine years on its drug Namodenoson. The company also began enrolling patients in a pivotal Phase III trial for the treatment in Israel, Europe, and the U.S. Namodenoson holds Orphan Drug and Fast Track designations.
18 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk (NVO) Today — Nov. 12, 2025: WeightWatchers to Offer Wegovy Pill, Canada Eyes Ozempic Copies, and the Latest Stock Move

WeightWatchers plans to offer Novo Nordisk’s oral Wegovy in the U.S. after its expected 2026 launch. Sandoz says unbranded Ozempic could reach Canada by June 2026, intensifying price competition. CVS dropped Lilly’s Zepbound from its preferred list, keeping Wegovy, prompting Lilly to move employees off CVS plans. Novo Nordisk shares traded at $49.76 late Wednesday, up slightly.
12 November 2025
·····
Tiny Biotech INTENSITY THERAPEUTICS Stock Skyrockets on Cancer Therapy Breakthrough – Experts See Big Upside

Biotech Bombshell: Intensity Therapeutics (INTS) Surges Nearly 400% on Major Cancer Trial News

Shares of Intensity Therapeutics closed at $1.32 on Oct. 30, surging nearly 395% intraday after Phase 1/2 trial data for INT230-6 showed a 75% disease-control rate in metastatic cancer. Over a billion shares traded, dwarfing the usual volume. After-hours, the price fell to around $0.90. The company’s market cap remains under $65 million.
31 October 2025
··
Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia Therapeutics (NTLA) Soars on CRISPR Breakthroughs – Latest Updates & Stock Outlook

Intellia’s NTLA-2001 gene editing therapy cut TTR protein by about 90% for three years in transthyretin amyloidosis patients, with improved outcomes and no new safety issues, according to data presented Sept. 25 and published in NEJM. Enrollment finished for the Phase 3 HAELO trial of NTLA-2002, with top-line results expected in 1H 2026. Intellia stock is up over 60% in 2025. Q2 revenue more than doubled to $14.25 million.
8 October 2025
···
uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure (QURE) Stock Soars on Huntington’s Breakthrough – Key Facts & 2025 Outlook

uniQure reported its gene therapy AMT-130 slowed Huntington’s disease progression by 75% over three years in high-dose patients. Trading in QURE shares was halted on volatility; the stock jumped from $4.45 to the mid-teens. The company secured a $175 million loan to fund AMT-130’s potential launch. Wall Street analysts rate the stock “Buy,” with targets averaging $37–$40.
24 September 2025
···
Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Breakthrough Cures, Big Deals, and Global Health Alerts – Biotech & Health News Roundup (Aug 16–17, 2025)

Pfizer’s sickle cell drug inclacumab failed a Phase 3 trial, missing its main goal and deepening setbacks from its $5.4 billion Global Blood Therapeutics acquisition. In contrast, Pfizer and Merck’s Padcev-Keytruda combo improved survival in muscle-invasive bladder cancer. Novo Nordisk’s Wegovy won FDA approval for treating metabolic dysfunction-associated steatohepatitis.
17 August 2025
······
Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

Breakthrough Drug Approved, Billion-Dollar Deals & Outbreak Alerts – Global Biotech & Health Roundup (Aug 12–13, 2025)

The FDA approved brensocatib (Brinsupri) as the first treatment for non-cystic fibrosis bronchiectasis, affecting about 500,000 Americans. Novartis reported positive Phase 3 results for ianalumab in Sjögren’s syndrome and immune thrombocytopenia. Biohaven’s OCD drug troriluzole failed in late-stage trials. Cardinal Health will acquire Solaris Health for $1.9 billion in cash.
13 August 2025
···
1 2

Stock Market Today

  • UK Stocks Edge Lower Amid Middle East Tensions and Weak Housing Data
    April 9, 2026, 12:37 PM EDT. London's FTSE 100 slipped 0.05% as renewed Iran-US tensions flared following Israeli strikes in Lebanon, leading Iran to block oil tanker passage through the Strait of Hormuz. Danske Bank warned of likely escalation due to persistent ceasefire disputes. UK housing market data showed worsening conditions, with the Royal Institution of Chartered Surveyors reporting a -23% house price balance in March, its weakest since December 2023, dampening prospects for UK-listed housebuilders. RICS and RBC Capital Markets highlighted deteriorating buyer demand and sales expectations amid rising mortgage costs and energy price volatility. On the corporate front, London Stock Exchange Group gained 0.18% after announcing a £900 million share buyback, while British American Tobacco shares fell 1.99% following the appointment of Dragos Constantinescu as CFO effective September 1.

Latest article

SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

SBTi Says Corporate Climate Targets Jumped 40% in 2025 as Asia Closes In on Europe

9 April 2026
The number of companies with Science Based Targets initiative-validated climate goals reached 9,764 by the end of 2025, up 40% from the previous year. Asia added 1,216 companies, nearly matching Europe’s increase. Europe held 49% of validated targets, Asia 36%, and North America 11%. Japan led single markets with 2,091 companies.
Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

Palantir Stock Drops as Michael Burry Says Anthropic Is ‘Eating Its Lunch’

9 April 2026
Palantir Technologies dropped about 7% Thursday after Michael Burry said Anthropic was overtaking it in enterprise AI, putting Palantir on track to lose $34 billion in market value. Anthropic reported its annualized revenue run rate had surged past $30 billion and launched new AI tools for businesses. Nearly one in four businesses on Ramp now pays for Anthropic, according to Ramp data. Palantir’s stock still trades at 395 times earnings.
Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

Salesforce Stock Hits Fresh 52-Week Low Despite AI Growth and $50 Billion Buyback

9 April 2026
Salesforce shares hit a new 52-week low Thursday, dropping 3.7% to $169.76 despite reporting 12% revenue growth and strong demand for its AI products. The broader software sector continued to slide, with the S&P 500 software and services index down about $1 trillion since January. Salesforce raised its buyback authorization to $50 billion and increased its dividend to 44 cents a share.
ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

ServiceNow Stock Hits Fresh 52-Week Low as Analysts Cut Targets Ahead of Earnings

9 April 2026
ServiceNow shares dropped 5.1% to $92.45 by 10:20 a.m. EDT Thursday, hitting a new 52-week low after analysts at Stifel, BTIG, and Goldman Sachs cut price targets citing weak federal spending and limited 2026 growth. The company announced it will integrate AI, data, security, and governance into all products ahead of first-quarter results due April 22.
SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

SoFi Technologies Stock Slips as Wall Street Cuts Targets Ahead of Q1 Earnings

9 April 2026
SoFi Technologies shares fell 1.9% to $16.18 Thursday after KBW and Wells Fargo cut price targets ahead of first-quarter results due April 29. The moves follow Muddy Waters’ short position and claims of accounting issues, which SoFi denies. Affirm and LendingClub also traded lower. Barclays and other banks have trimmed targets as concerns mount over credit quality and sector valuations.
Go toTop